Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

Incyte Corporation1,469 enrolled

Overview

The purpose of this prospective, longitudinal, noninterventional study is to describe clinical characteristics, evolution of disease burden, and treatment patterns in patients with select subcategories of essential thrombocythemia (ET) or myelofibrosis (MF).

Study Type

OBSERVATIONAL

Enrollment

1,469

Conditions

MPN (Myeloproliferative Neoplasms)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * MF cohort: Diagnosis of MF and low-risk using DIPSS risk categorization OR intermediate-1 risk by DIPSS by reason of age alone. * ET cohort: Diagnosis of ET and age ≥ 60 years OR history of thromboembolic events OR currently receiving ET-directed therapy (eg, hydroxyurea, anagrelide, interferon, busulfan, ruxolitinib, etc). * Willing and able to provide written informed consent. * Willing and able to complete patient assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel. * Under the supervision of a physician for the current care of MF or ET. Exclusion Criteria: * Individuals who are participating in blinded investigational drug studies. * Individuals who are participating in Incyte investigational/interventional drug trials (company- or investigator-sponsored studies) until they have completed the 30-day end of study visit. * Life expectancy ≤ 6 months. * Diagnosis of secondary acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, or secondary thrombocytosis.

Locations (116)

Outcomes

Primary Outcomes

Description of the clinical characteristics and evolution of disease burden in essential thrombocythemia (ET) and myelofibrosis (MF) patients

Time frame: Approximately every 6 months through end of study, up to approximately 36 months